Navigation Links
ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease Drug
Date:6/14/2017

ACEA Biosciences today announced the completion of its Phase 1 clinical study of AC0058, a novel irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor, which is in development for the treatment of B cell-related autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus. Fifty-six (56) healthy subjects participated in the double-blind, placebo-controlled trial, which served to evaluate AC0058’s safety, tolerability, pharmacokinetics, pharmacodynamics, and target engagement, when administered orally in either a single ascending dose (SAD), or seven-day multiple ascending doses (MAD). Both the SAD and MAD trials successfully met their primary endpoints, and the maximum tolerated dose was not reached in either case. AC0058 was found to be safe and well-tolerated.

"AC0058 is another result of ACEA’s unique drug discovery and development capabilities which have, over the past two years, advanced multiple molecules into the clinic in both China and the United States," said Xiao Xu, M.D., Chief Executive Officer of ACEA. "By leveraging our expertise in covalent tyrosine kinase inhibitors, we’ve been able to rapidly develop AC0058, and the properties of this small molecule make it well-suited for the treatment of chronic diseases, where safety is paramount. Based on the preliminary and encouraging safety and PK/PD data, and the fact that AC0058 has a profile that is amenable to chronic oral dosing, we are moving forward with plans to initiate Phase 2 clinical trials. We’ll be announcing additional details from the trial and complete data outcomes at future clinical meetings and conferences.”

About AC0058
AC0058 is a small molecule that selectively inhibits Bruton's tyrosine kinase (BTK) phosphorylation and its subsequent downstream signaling. In preclinical studies AC0058 was shown to inhibit lymphocyte (predominantly B-cell) activation as well as inflammatory cytokine production in monocytes.

About ACEA Biosciences
ACEA Biosciences, Inc. (ACEA) is a privately owned biotechnology company focused on the development and commercialization of innovative cell analysis instrumentation for life sciences, and on the discovery and development of novel pharmaceutical products for the treatment of chronic diseases. ACEA’s instruments, xCELLigence® and NovoCyte®, are used in preclinical drug discovery and development, toxicology, safety pharmacology, disease studies, and basic academic research. More than 3,000 instruments have been placed globally, leading to >1,350 peer-reviewed publications from both academia and the pharmaceutical industry in diverse applications spanning everything from cancer immunotherapy and cardiotoxicity to chemotactic migration and GPCR inhibition. ACEA has leveraged its technology platforms to develop a robust pipeline of clinical and preclinical small molecules for the treatment of cancer and autoimmune diseases, with two clinical stage programs running in China and the USA. ACEA Biosciences is headquartered in San Diego, California with world-class manufacturing operations in Hangzhou, China.

For more information on ACEA’s ongoing clinical trials, please visit click here.

Source: ACEA Biosciences

ACEA Biosciences, Inc.
Xiao Xu
xxu(at)aceabio.com

Read the full story at http://www.prweb.com/releases/2017/06/prweb14423401.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
2. Northstar Biosciences Launches All Natural Skincare Solutions
3. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
4. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
5. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
6. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
7. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
8. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
10. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
11. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... ... September 09, 2019 , ... ... trial randomization and drug supply chain management, today announced its new technology partnership ... sciences industry. , “The integration between Veeva Vault EDC and our IRT will ...
(Date:9/9/2019)... ... 09, 2019 , ... Visikol CEO Dr. Michael Johnson recently gave a ... to characterize 3D cell culture models. The inherent problem of characterizing 3D cell culture ... to image through and therefore traditional wide-field or even confocal microscopy only tells you ...
(Date:9/4/2019)... (PRWEB) , ... September 03, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... Director, Science & Technology will present at the upcoming Nordic Life Science ...
(Date:8/29/2019)... Kan. (PRWEB) , ... August 28, 2019 , ... ... expertise and wide-ranging DuPont™ Danisco® ingredient solutions to attendees at the International Baking ... to solve today’s baking challenges from optimizing production efficiency to cost and waste ...
Breaking Biology Technology:
(Date:8/14/2019)... ... , ... Gateway Genomics , a leading developer of direct-to-consumer genetic tests ... annual Inc. 500|5000 list of fastest growing private companies, in the first year ... and generating revenue by March 31, 2015. Ranking in the list is determined by ...
(Date:8/14/2019)... Calif. (PRWEB) , ... August 13, 2019 , ... Dr. Julie Reck of Veterinary ... to her patients. Her first stem cell patient, her own geriatric Australian Shepherd, ... According to Dr. Reck, Simon wanted to play but his body was weak, and he ...
(Date:8/6/2019)... , ... August 06, 2019 , ... ... a computational modeling system that could have far-reaching implications for personalized medicine, especially ... squares regression (PLSR), is able to predict which stem cell donors and manipulation ...
Breaking Biology News(10 mins):